Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for breast cancer screening
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer screening or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on breast cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
reviews showed that women aged 39 to 49 years derived the lowest absolute benefit in terms of deaths prevented ( , ) ( ). Observational studies showed larger relative reductions in breastcancer mortality ( ). Evidence from RCTs (fair quality) and observational studies (poor quality) did not show a reduction in the incidence of advanced disease with breastcancerscreening in women aged 39 to 49 years (pooled results from 4 RCTs: relative risk, 0.98 [95% CI, 0.74 to 1.37]) ( ). Screening intervals (...) diagnostic accuracy characteristics regarding cancer detection, false-positive results, recalls, and biopsy rates. Compared with conventional mammography, DBT seems to reduce recall rates and increase cancer detection ( ). The effect of these more sensitive imaging methods on the spectrum of detected disease and associated screening benefits and harms, including overdiagnosis, is not known. Alternative or Adjunctive Tests to Screening Mammography in Women Who Have Dense Breasts Increased breast density
between the ages of 10 years and 14 years appear to be at greatest risk of future development of breastcancer. General Considerations for Screening The goal of screening for cancer is to detect preclinical disease in healthy, asymptomatic patients to prevent adverse outcomes, improve survival, and avoid the need for more intensive treatments. Screening tests have both benefits (eg, improved health outcomes) and adverse consequences (eg, cost, anxiety, inconvenience, false-positive results, and other (...) test-specific harms such as overdiagnosis and overtreatment). Breast self-examination, breast self-awareness, clinical breast examination, and mammography all have been used alone or in combination to screen for breastcancer. In general, more intensive screening detects more disease. Screening intensity can be increased by combining multiple screening methods, extending screening over a wider age range, or repeating the screening test more frequently. However, more frequent use of the same
also benefit from supplemental screening. The recommendations for supplemental screening for women at intermediate risk of breastcancer, including those with a personal history of breastcancer, a history of lobular carcinoma in situ or ADH, those with an intermediate family history and a lifetime risk of 15% to 20%, or women with dense breasts continues to be an area of debate . Mammography and DBT Annual screening mammography is recommended for women with biopsy-proven lobular neoplasia (...) and with IV contrast Usually Not Appropriate O MRI breast without IV contrast Usually Not Appropriate O FDG-PEM Usually Not Appropriate ???? Tc-99m sestamibi MBI Usually Not Appropriate ??? Variant 2: Breastcancerscreening. Intermediate-risk women: women with personal history of breastcancer, lobular neoplasia, atypical ductal hyperplasia, or 15% to 20% lifetime risk of breastcancer. Procedure Appropriateness Category Relative Radiation Level Mammography screening Usually Appropriate ?? Digital breast
Recommendations on screening for breastcancer in women 40-74 years of age who are not at increased risk Recommendations on screening for breastcancer in women aged 40–74 years who are not at increased risk for breastcancer | CMAJ Main menu User menu Search Search for this keyword Search for this keyword Guideline Recommendations on screening for breastcancer in women aged 40–74 years who are not at increased risk for breastcancer Scott Klarenbach , Nicki Sims-Jones , Gabriela Lewin (...) POINTS Low-certainty evidence indicates that screening for breastcancer with mammography results in a modest reduction in breastcancer mortality for women aged 40 to 74 years; the absolute benefit is lowest for women younger than 50 years. Screening may lead to overdiagnosis, resulting in unnecessary treatment of cancer that would not have caused harm in a woman’s lifetime and false-positive results that can lead to both physical and psychological consequences; overdiagnosis and false-positives
Magnetic Resonance Imaging as an Adjunct to Mammography for BreastCancerScreening in Women at Less Than High Risk for BreastCancer Magnetic Resonance Imaging as an Adjunct to Mammography for BreastCancerScreening in Women at Less Than High Risk for BreastCancer - Health Quality Ontario (HQO) Let's make our health system healthier Open Menu Quick Links Search Search A A A Evidence to Improve Care Share: Magnetic Resonance Imaging as an Adjunct to Mammography for BreastCancerScreening (...) in Women at Less Than High Risk for BreastCancer Ontario Health Technology Advisory Committee Recommendation The Ontario Health Technology Advisory Committee recommends against publicly funding screeningbreast magnetic resonance imaging (MRI) as an adjunct to screening mammography for women who are at less than high risk for breastcancer and who have no personal history of breastcancerBreastcancer is the most common cancer among Canadian women. The most common form of screening for breastcancer
. Importantly, accurate and reliable risk estimation and strati?cation for malignancy risk is highly problematicformostofthegenesidenti?edinthesepanels. The following genes might have moderate- to high- penetrance germline mutations for breast or ovarian cancer: p53, PTEN, CDH1, PALB2, CHEK2, ATM, RAD51C, STK11, RAD51D, BRIP1, MLH1, MSH2, MSH6 and PMS2. Prevention and screening strategies for these mutations are summarised in Table 1—due to limited research in individuals harbouring these mutations (...) Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian Hereditary Cancer Syndromes PreventionandscreeninginBRCAmutationcarriersand otherbreast/ovarianhereditarycancersyndromes: ESMOClinicalPracticeGuidelinesforcancerprevention andscreening † S.Paluch-Shimon 1 ,F.Cardoso 2 ,C.Sessa 3 ,J.Balmana 4 ,M.J.Cardoso 2 ,F.Gilbert 5 &E.Senkus 6 , onbehalfoftheESMOGuidelinesCommittee * 1 DivisionofOncologyandtheDrPinchasBorensteinTalpiotMedicalLeadershipProgram,ShebaMedicalCenter
choose to begin biennial screening between the ages of 40 and 49 years. • For women who are at average risk for breastcancer , most of the benefit of mammography results from biennial screening during ages 50 to 74 years. Of all of the age groups, women aged 60 to 69 2016 5. Mammography in combination with breast ultrasonography versus mammography for breastcancerscreening in women at average risk. BACKGROUND: Breastcancer is the most common malignantdisease diagnosed in women worldwide (...) Breastcancerscreening Top results for breastcancerscreening - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might
Improvement in risk prediction, early detection and prevention of breastcancer in the NHS BreastScreening Programme and family history clinics: a dual cohort study Improvement in risk prediction, early detection and prevention of breastcancer in the NHS BreastScreening Programme and family history clinics:a dual cohort study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could
of a woman's lifetime. ACS selected the Duke University Evidence Synthesis Group to conduct an independent systematic evidence review after a response to a request for proposals, and commissioned the BreastCancer Surveillance Consortium (BCSC) to update previously published analyses related to the screening interval and outcomes. The ACS Surveillance and Health Services Research Program provided supplementary data on disease burden using data from the Surveillance, Epidemiology, and End Results (SEER (...) Screening for BreastCancer in Women at Average Risk* Screening for BreastCancer in Women at Average Risk | National Guideline Clearinghouse success fail JUL Aug 12 2018 2019 30 Sep 2016 - 13 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed
System. Recall rate was lower with DBT than with FFDM (7.9% vs. 10.9%; 95% confidence interval [CI], 0.77–0.85), but there was no difference in the rates of biopsy or the detection of benign or malignantdisease.[ ] Characteristics of Cancers Detected by Breast Imaging Regardless of stage, nodal status, and tumor size, screen-detected cancers have a better prognosis than those diagnosed outside of screening.[ ] This suggests that they are biologically less lethal (perhaps slower growing and less (...) of Effect : Between 20% and 50% of screen-detected cancers represent overdiagnosis based on patient age, life expectancy, and tumor type (ductal carcinoma in situ and/or invasive).[ , ] These estimates are based on two imperfect analytic methods:[ , ] Long-term follow-up of RCTs of screening. The calculation of excess incidence in large screening programs.[ , ] Study Design : RCTs, descriptive, population-based comparisons, autopsy series, and series of mammary reduction specimens. False Positives
; 16(20). 2016 Authors' conclusions It remains uncertain if the use of adjunct screeningbreast MRI in women at less than high risk (average or higher than average risk) for breastcancer will reduce breastcancer–related mortality without significant increases in unnecessary follow-up testing and treatment. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH BreastNeoplasms; Humans; Magnetic Resonance Imaging; Mammography; Risk Language Published English Country (...) Magnetic resonance imaging as an adjunct to mammography for breastcancerscreening in women atless than high risk for breastcancer: a health technology assessment Magnetic resonance imaging as an adjunct to mammography for breastcancerscreening in women at less than high risk for breastcancer: a health technology assessment Magnetic resonance imaging as an adjunct to mammography for breastcancerscreening in women at less than high risk for breastcancer: a health technology assessment
over precisely which screening services should be provided and to whom, these methods are frequently used in contemporary practice. 2–4 Outcomes of screening for breastcancer such as tumour detection and mortality must be put into context of the harms and costs of false - positive results, overdiagnosis and overtreatment. Consideration of benefi ts, harms and costs is complicated by variations in risk factors and in the types and stages of cancer. Any positive result from screening has emo- tional (...) Care (2001). 5,6 The absence of current Canadian recommendations, the recent contro- versy over the best way to screen for breastcancer among women at average risk of the disease, 7,8 the availability of new technologies such as magnetic resonance imaging (MRI) and a recent review of the evidence 9 were the basis for selecting this topic for an update by the revitalized Canadian Task Force on Preventive Health Care. Recommendations are presented for the use of mammography, MRI, breast self
Digital Tomosynthesis for the Screening and Diagnosis of BreastCancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Digital Tomosynthesis for the Screening and Diagnosis of BreastCancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Digital Tomosynthesis for the Screening and Diagnosis of BreastCancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Digital Tomosynthesis for the Screening and Diagnosis of BreastCancer (...) for breastcancer diagnosis? What is the comparative clinical effectiveness of synthetic 2D mammography compared with conventional 2D digital mammography obtained with 3D digital tomosynthesis? What is the cost effectiveness of 3D digital tomosynthesis with or without 2D mammography compared with 2D mammography alone for breastcancerscreening or diagnosis? What are the evidence-based guidelines regarding the use of 3D digital tomosynthesis for breastcancerscreening and diagnosis? Key Message Seven
improve patient management and health outcomes? Are there any safety issues associated with the use of DBT? Have definitive patient selection criteria been established for DBT for screening or diagnosis of breastcancer? Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH BreastNeoplasms; Humans; Mammography; Tomography, X-Ray Language Published English Country of organisation United States English summary An English language summary (...) Digital breast tomosynthesis for breastcancer diagnosis and screening Digital breast tomosynthesis for breastcancer diagnosis and screening Digital breast tomosynthesis for breastcancer diagnosis and screening HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Digital breast tomosynthesis for breastcancer diagnosis and screening. Lansdale
or 42 CommGuideCancerMCIPsycINFO 1. (mass screening or multiphasic screening or screen or screened or screening or "early detection of cancer").mp. 2. ((neoplasm* or ductal breastcarcinoma* or "hereditary breast and ovarian cancer syndrome") and (diagnosis or prevention)).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] 3. ((adenoma* or neoplasia or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical (...) or screening).ti,ab. or "early detection of cancer"/ 20. (neoplasms/ or breastneoplasms/ or colorectal neoplasms/ or uterine cervical neoplasms/ or carcinoma, ductal, breast/ or "hereditary breast and ovarian cancer syndrome"/ or inflammatory breastneoplasms/ or colonic neoplasms/ or rectal neoplasms/) and (di or pc).fs. 21. ((adenoma* or neoplasia or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical or cervix or colon or colorectal or crc)).ti,ab. 22. 20 or 21 23
also recognized that the population of high-risk women is very small, with a high burden of disease, and that this technology may be particularly helpful in women who have a contraindication to MRI, the current standard of care. Ultrasound as an Adjunct to Mammography for BreastCancerScreening: OHTAC Recommendation. July 2016; pp. 1–4 2 Decision Determinants for Ultrasound as an Adjunct to Mammography for BreastCancerScreening Decision Criteria Subcriteria Decision Determinants Considerations (...) of the disease. Need How large is the need for this health technology/intervention? Women at average risk for developing breastcancer currently only receive mammography screening for breastcancer. Mammography screening is not perfect, and therefore a number of these women may have their cancers missed by mammography due to factors such as dense breasts and younger age. Currently, 1.15 million women in Ontario aged 50 to 74 years are screened with mammography annually. Women at high risk for breastcancer
Two-view digital breast tomosynthesis versus digital mammography in a population-based breastcancerscreening programme (To-Be): a randomised, controlled trial Digital breast tomosynthesis is an advancement of mammography, and has the potential to overcome limitations of standard digital mammography. This study aimed to compare first-generation digital breast tomo-synthesis including two-dimensional (2D) synthetic mammograms versus digital mammography in a population-based screening (...) cancer, stratified by screening technique (ie, digital breast tomosynthesis and digital mammography). A log-binomial regression model was used to estimate the efficacy of digital breast tomosynthesis versus digital mammography, defined as the crude risk ratios (RRs) with 95% CIs for screen-detected breastcancer for women screened during the recruitment period. A per-protocol approach was used in the analyses. This trial is registered at ClinicalTrials.gov, number NCT02835625, and is closed
Evaluations 1. Ahern CH, Shih YC, Dong W, Parmigiani G, Shen Y. Cost-effectiveness of alternative strategies for integrating MRI into breastcancerscreening for women at high risk. Br J Cancer [Internet]. 2014 Oct 14 [cited 2015 May 6];111(8):1542-51. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200098 PubMed: PM25137022 Guidelines and Recommendations 2. Institute for Clinical Systems Improvement (ICSI). Health Care Guideline: Diagnosis of BreastDisease 14 th edition [Inetrnet (...) Concurrent versus Sequential Digital Mammography and MRI for BreastCancerScreening in High-Risk Patients Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed